Glicana 100 Tablet - Canagliflozin 100mg | Incepta Pharmaceuticals

What is Glicana 100 Tablet?

Glicana 100 Tablet is an oral anti-diabetic medication manufactured by Incepta Pharmaceuticals Ltd., containing Canagliflozin Hemihydrate as its active ingredient. It belongs to the SGLT2 inhibitor class of drugs and is used as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.

Generic Name and Composition

Each Glicana 100 Tablet contains Canagliflozin Hemihydrate equivalent to 100 mg of Canagliflozin.

Indications

• Adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus
• May be used as monotherapy or in combination with other anti-diabetic agents such as metformin, sulfonylureas, or insulin
• Reduction of risk of major adverse cardiovascular events in adults with type 2 diabetes mellitus and established cardiovascular disease (in select patients, as advised by physician)

How It Works - Mechanism of Action

Canagliflozin inhibits sodium-glucose co-transporter 2 (SGLT2), the transporter responsible for the majority of glucose reabsorption in the proximal renal tubule. By blocking SGLT2, Canagliflozin reduces renal glucose reabsorption and increases urinary glucose excretion, thereby lowering plasma glucose levels in an insulin-independent manner.

Dosage and Administration

• Usual starting dose: 100 mg once daily, taken before the first meal of the day
• In patients tolerating the 100 mg dose with eGFR/CrCl above 60 mL/min who require additional glycemic control, the dose may be increased to 300 mg once daily
• No dose adjustment needed for mild renal impairment; use is generally not recommended in patients with significant renal impairment - follow physician's advice
• To be taken exactly as prescribed by the physician; do not alter dose without medical advice

Side Effects

Common: Female genital mycotic infections, urinary tract infection, increased urination, thirst, nausea

Uncommon: Male genital mycotic infections, hypoglycemia (when combined with insulin or sulfonylureas), volume depletion-related effects (dizziness, postural hypotension), constipation

Rare: Diabetic ketoacidosis, acute kidney injury, bone fracture, lower limb amputation (increased risk reported with canagliflozin), hypersensitivity reactions, Fournier's gangrene (necrotizing fasciitis of the perineum)

Drug Interactions

Diuretics: Concomitant use with loop diuretics may increase risk of volume depletion and hypotension

Insulin and Insulin Secretagogues: Combination increases risk of hypoglycemia; dose reduction of insulin/secretagogue may be required

UGT Enzyme Inducers (e.g., rifampin, phenytoin, phenobarbital, ritonavir): May reduce efficacy of Canagliflozin by increasing its metabolism; dose adjustment may be needed

Digoxin: Canagliflozin may modestly increase digoxin levels; monitoring advised

Contraindications

• Known hypersensitivity to Canagliflozin or any excipients
• Severe renal impairment, end-stage renal disease, or patients on dialysis
• Type 1 diabetes mellitus
• Diabetic ketoacidosis

Pregnancy and Lactation

Canagliflozin is not recommended during pregnancy, particularly in the second and third trimesters, due to potential risk to the developing kidneys. It is not recommended during breastfeeding. Please consult your physician for appropriate alternative therapy if pregnant, planning pregnancy, or breastfeeding.

Precautions and Warnings

• Monitor renal function periodically during treatment
• Risk of volume depletion, especially in elderly patients, those on diuretics, or with renal impairment - ensure adequate hydration
• Increased risk of lower limb amputation reported - inform physician of any foot ulcers, infections, or pain
• Watch for signs of ketoacidosis even with normal or mildly elevated blood glucose
• Increased risk of genital mycotic infections - maintain genital hygiene
• Rare cases of Fournier's gangrene reported - seek immediate medical attention for severe genital/perineal pain, tenderness, or swelling with fever or malaise
• Not for use in type 1 diabetes

Overdose

In case of suspected overdose, contact a physician or seek emergency medical care immediately. Management is generally supportive, including monitoring of clinical status and standard supportive measures. Hemodialysis has not been studied as a treatment for canagliflozin overdose.

Storage Instructions

• Store at room temperature, below 30°C
• Protect from light and moisture
• Keep in original packaging until time of use
• Keep out of reach of children

Frequently Asked Questions

Q1: What is Glicana 100 Tablet used for?
A1: Glicana 100 Tablet (Canagliflozin) is used along with diet and exercise to improve blood sugar control in adults with type 2 diabetes mellitus.

Q2: When should I take Glicana 100 Tablet?
A2: It is usually taken once daily before the first meal of the day, as directed by your physician.

Q3: Can Glicana 100 Tablet cause low blood sugar?
A3: When used alone, Canagliflozin has a low risk of hypoglycemia. However, the risk increases when combined with insulin or sulfonylureas. Always follow your physician's dosing instructions.

Q4: How is Glicana different from Dapaglip (Dapagliflozin) by Incepta?
A4: Both Glicana (Canagliflozin) and Dapaglip (Dapagliflozin) are SGLT2 inhibitors manufactured by Incepta that work via a similar mechanism to lower blood glucose by increasing urinary glucose excretion. They differ in molecular structure, available strengths, and certain pharmacokinetic properties. Your physician will determine which is appropriate based on your individual health profile, renal function, and treatment goals.

Medical Disclaimer

This medicine is available only with a valid prescription from a registered physician (Rx only). The information provided here is for educational purposes and does not replace professional medical advice. DiabetesStore.com.bd is a licensed online pharmacy in Bangladesh. Please consult your doctor before starting, stopping, or changing any medication.